SJX-653 – A Novel NK3 Antagonist
SJX-653 is a novel and selective small-molecule antagonist of the neurokinin-3 (NK3) receptor in clinical development as a once-daily non-hormonal therapy for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
SJX-653 is currently being investigated in Phase 1 clinical studies designed to characterize its safety, tolerability and pharmacokinetic profile in postmenopausal women, the target population for future studies in patients suffering from moderate to severe vasomotor symptoms. In addition, we are conducting a clinical study in men designed principally to characterize the effect of SJX-653 on pharmacodynamic markers known to be associated with NK3 receptor engagement. SJX-653 has been well characterized in preclinical studies and exhibits excellent pharmaceutical properties.